Oh Min Woo, Park Ji-In, Shim Ga Yang, Kong Hyun-Ho
Department of Rehabilitation Medicine, Chungbuk National University Hospital.
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital.
Arch Phys Med Rehabil. 2025 Feb;106(2):300-310. doi: 10.1016/j.apmr.2024.07.005. Epub 2024 Jul 18.
This study aims to assess the effectiveness of 5% dextrose (D5W) in comparison to corticosteroids for treating carpal tunnel syndrome (CTS).
A comprehensive systematic search was conducted across MEDLINE (PubMed), Embase, and the Cochrane Central Register of Controlled Trials on November 13, 2023. These were supplemented by manual searches using Google Scholar.
Two independent authors reviewed the literature, resolving any discrepancies through detailed discussions and consultation with a third author.
Data on primary outcomes (pain assessment) and secondary outcomes (symptom severity and functional status using the Boston Carpal Tunnel Questionnaire, electrophysiologic measures, cross-sectional area, and adverse effects) were extracted independently by the 2 authors (M.W. and H.H.).
The analysis included 4 randomized controlled trials and 1 quasi-experimental study, encompassing a total of 212 patients (220 hands) with mild to moderate CTS.
Within 3 months, the D5W injections showed a statistically significant improvement in functional status compared to the corticosteroids with a standard mean difference of -0.34 (95% CI, -0.62 to -0.05). D5W was associated with fewer adverse incidents than corticosteroids (risk ratio, 0.13; 95% CI: 0.03-0.51). No difference was observed between the 2 treatments in other areas.
For patients with mild to moderate CTS, D5W injections were more effective than corticosteroid injections in improving functional status and demonstrated fewer adverse effects. D5W injections also paralleled corticosteroids in pain reduction, symptom severity, electrodiagnostic measures, and cross-sectional area of nerve, recommending D5W as a preferred treatment for mild to moderate CTS.
本研究旨在评估5%葡萄糖(D5W)与皮质类固醇相比治疗腕管综合征(CTS)的有效性。
2023年11月13日在MEDLINE(PubMed)、Embase和Cochrane对照试验中央注册库进行了全面的系统检索。此外,还通过谷歌学术进行了手动检索作为补充。
两位独立作者对文献进行了审查,通过详细讨论并与第三位作者协商解决了任何分歧。
两位作者(M.W.和H.H.)独立提取了关于主要结局(疼痛评估)和次要结局(使用波士顿腕管问卷评估症状严重程度和功能状态、电生理测量、横截面积以及不良反应)的数据。
分析纳入了4项随机对照试验和1项准实验研究,共212例轻度至中度CTS患者(220只手)。
在3个月内,与皮质类固醇相比,D5W注射在功能状态方面显示出统计学上的显著改善,标准平均差为-0.34(95%CI,-0.62至-0.05)。D5W相关的不良事件比皮质类固醇少(风险比,0.13;95%CI:0.03 - 0.51)。在其他方面,两种治疗方法之间未观察到差异。
对于轻度至中度CTS患者,D5W注射在改善功能状态方面比皮质类固醇注射更有效,且不良反应更少。D5W注射在减轻疼痛、症状严重程度、电诊断测量以及神经横截面积方面也与皮质类固醇相当,推荐D5W作为轻度至中度CTS的首选治疗方法。